sofituzumab vedotin

Sofituzumab vedotin is an investigational antibody-drug conjugate (ADC) developed by Genentech/Roche for the treatment of cancers that overexpress MUC16, such as ovarian and pancreatic cancer. The drug consists of a humanized anti-MUC16 (CA125) monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to MUC16 on tumor cells, the ADC is internalized and releases MMAE, which inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. Additional antitumor effects may include signal transduction inhibition, as well as immune-mediated mechanisms like antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity[1][3][4][6].

Other names

Anti-MUC16 ADC MMAEAnti-MUC-16 ADC MMAEAnti-MUC 16 ADC MMAEAnti-MUC16 mAb MMAEAnti-MUC-16 mAb MMAEAnti-MUC 16 mAb MMAEAnti-MUC16 MMAE ADCAnti-MUC-16 MMAE ADCAnti-MUC 16 MMAE ADCAnti-MUC16 monoclonal antibody MMAEAnti-MUC-16 monoclonal antibody MMAEAnti-MUC 16 monoclonal antibody MMAEAnti-MUC16 monoclonal antibody monomethyl auristatin E conjugateAnti-MUC-16 monoclonal antibody monomethyl auristatin E conjugateAnti-MUC 16 monoclonal antibody monomethyl auristatin E conjugateAnti-MUC16 monoclonal antibody vedotinAnti-MUC-16 monoclonal antibody vedotinAnti-MUC 16 monoclonal antibody vedotinMMAE anti-MUC16 mAbMMAE anti-MUC16 monoclonal antibody conjugateMonomethyl auristatin E anti-MUC16 monoclonal antibody conjugateVedotin anti-MUC16 monoclonal antibody